Florida Amendment 3 Campaign: The Fight for Adult-Use Cannabis Legalization

Executive Summary

Florida's Amendment 3, which appeared on the November 2024 ballot, sought to legalize recreational marijuana for adults 21 and older but failed to reach the required 60% supermajority threshold despite garnering approximately 56% voter support. The campaign became one of the most expensive and contentious ballot initiatives in Florida history, with over $150 million spent by proponents and opponents combined. The measure was backed primarily by Trulieve Cannabis Corp., Florida's largest medical marijuana operator, which contributed more than $145 million to the Smart & Safe Florida political committee. Governor Ron DeSantis mounted an unprecedented state-funded opposition campaign, deploying state agencies and resources to defeat the measure. The controversy surrounding the campaign intensified in August 2026 when a grand jury report alleged that the DeSantis administration misused approximately $10 million in Medicaid funds to finance anti-Amendment 3 advertising and outreach efforts during the 2024 campaign period.

Why This Matters

The Florida Amendment 3 campaign represents a pivotal moment in cannabis policy, demonstrating both the political obstacles to legalization in conservative states and the unprecedented role of state government opposition in ballot measure campaigns. Florida's population of approximately 22 million people made Amendment 3 one of the largest single-state legalization votes in U.S. history. Had it passed, Florida would have become the 25th state to legalize adult-use cannabis and created what analysts projected would be a $6 billion annual market by 2028. The state's existing medical marijuana program, established under Amendment 2 in 2016, serves over 800,000 registered patients through 25 licensed Medical Marijuana Treatment Centers operating more than 600 dispensaries statewide. The campaign's financial scale exceeded all previous Florida ballot initiatives. Trulieve's $145 million investment represented the largest single-company expenditure on any state cannabis ballot measure nationwide. The opposition campaign, funded partly through what the 2026 grand jury characterized as improper use of state Medicaid dollars, raised questions about the appropriate role of government resources in ballot measure campaigns. For cannabis operators, the defeat represented a significant setback to expansion plans. Multi-state operators including Curaleaf, Ayr Wellness, and Verano Holdings had made strategic investments in Florida's medical market anticipating adult-use legalization. The failure of Amendment 3 left these companies with limited growth prospects in a medical-only market with restrictive vertical integration requirements. Patient advocates expressed concern that the campaign's focus on recreational use overshadowed ongoing medical program issues, including high product costs, limited qualifying conditions, and the absence of smokable flower options until 2019. The defeat also meant continued criminalization for possession of small amounts, with Florida law treating possession of more than 20 grams as a felony punishable by up to five years imprisonment.

Background and History

Florida's path to the Amendment 3 campaign began with decades of incremental cannabis policy reform, marked by successful medical marijuana initiatives, legislative battles, and evolving public opinion.

Early Medical Marijuana Efforts (2014-2016)

Florida voters first considered medical marijuana legalization in November 2014 through Amendment 2, sponsored by the political committee United for Care and funded primarily by Orlando trial attorney John Morgan. That measure received 57.6% support, falling short of the 60% constitutional amendment threshold required under Article XI, Section 5 of the Florida Constitution. The 2014 measure would have allowed physicians to recommend medical marijuana for debilitating conditions. In 2014, the Florida Legislature passed the Compassionate Medical Cannabis Act, creating a limited low-THC cannabis program for patients with cancer or conditions causing chronic seizures or severe muscle spasms. The law, codified at Florida Statutes § 381.986, authorized five nurseries to cultivate, process, and dispense low-THC cannabis containing 0.8% or less THC and more than 10% CBD.

Amendment 2 Success (2016)

A revised Amendment 2 appeared on the November 2016 ballot with broader language allowing medical marijuana for a wider range of debilitating conditions. The measure passed with 71.3% support, adding Article X, Section 29 to the Florida Constitution. The amendment required the Florida Department of Health to register and regulate Medical Marijuana Treatment Centers and issue medical marijuana use authorization cards to qualifying patients. The 2016 amendment defined debilitating medical conditions to include cancer, epilepsy, glaucoma, HIV/AIDS, post-traumatic stress disorder, amyotrophic lateral sclerosis, Crohn's disease, Parkinson's disease, multiple sclerosis, and other conditions of the same kind or class or comparable symptoms. It granted physicians discretion to recommend medical marijuana for other conditions.

Implementation Battles (2017-2019)

The Florida Legislature implemented Amendment 2 through Senate Bill 8A in June 2017, establishing the regulatory framework under Florida Statutes Chapter 381. The law imposed a 90-day waiting period for physician recommendations, capped the number of licensed operators, and initially prohibited smokable marijuana flower. John Morgan and other advocates challenged the smoking ban as inconsistent with voter intent. In March 2018, Leon County Circuit Court Judge Karen Gievers ruled in Cathy Jordan, et al. v. Florida Department of Health that the smoking prohibition violated Amendment 2. The DeSantis administration declined to appeal, and the Legislature repealed the ban in March 2019 through Senate Bill 182. The vertical integration requirement mandating that licensees handle all cultivation, processing, and retail operations remained controversial. The Department of Health issued 22 licenses by 2022, with Trulieve emerging as the dominant operator controlling approximately 50% of market share.

Amendment 3 Drafting and Qualification (2022-2023)

Smart & Safe Florida, a political committee formed in April 2022 and funded almost exclusively by Trulieve, began gathering petition signatures for what would become Amendment 3. The proposed amendment's ballot language stated: "Allows adults 21 years or older to possess, purchase, or use marijuana products and marijuana accessories for non-medical personal consumption by smoking, ingestion, or otherwise." The measure required the Florida Department of Health to register entities to acquire, cultivate, process, manufacture, sell, and distribute marijuana products and accessories. Critically, it did not create new licenses or disrupt the existing vertical integration structure, meaning only current Medical Marijuana Treatment Centers would be positioned to serve the adult-use market. Smart & Safe Florida submitted 997,279 verified signatures by February 2023, exceeding the 891,523 required threshold. The Florida Supreme Court reviewed the ballot language under its advisory jurisdiction per Article XI, Section 3 of the Florida Constitution. In April 2024, the Court approved the amendment for the November ballot in a 5-2 decision, finding the title and summary met the single-subject requirement and were not misleading.

Campaign Period (2024)

The official campaign period from May through November 2024 saw unprecedented spending and state government involvement. Trulieve CEO Kim Rivers publicly stated the company's investment aimed to create a regulated adult-use market and end criminalization of personal possession. By October 2024, Trulieve had contributed $143 million to Smart & Safe Florida, with additional contributions from Curaleaf, AYR Wellness, and Parallel totaling approximately $2 million combined. Governor DeSantis announced his opposition in May 2024, characterizing the amendment as a corporate monopoly scheme benefiting Trulieve. The administration launched a multi-agency opposition effort coordinated through the Executive Office of the Governor. The Florida Department of Transportation erected highway signs warning against Amendment 3. The Florida Department of Health created a webpage titled "The Truth About Amendment 3" featuring claims about public health risks. The Florida Agency for Health Care Administration, which administers the state's $34 billion Medicaid program, produced television and radio advertisements opposing Amendment 3. These advertisements aired statewide from September through early November 2024. According to the August 2026 grand jury report, AHCA spent approximately $10 million on anti-Amendment 3 media buys, funded through its Medicaid administrative budget rather than appropriated campaign funds. Opposition groups including Vote No on 3 and Keep Florida Clean received contributions from casino operator Genting Malaysia and Republican donor Ronald Cameron. The Florida Republican Party incorporated Amendment 3 opposition into its coordinated campaign messaging.

Election Results and Aftermath (November 2024)

On November 5, 2024, Amendment 3 received 5,893,417 votes in favor (55.9%) and 4,651,786 votes against (44.1%), falling approximately 423,000 votes short of the 60% threshold. The measure performed strongest in South Florida counties including Miami-Dade, Broward, and Palm Beach, where support exceeded 60%. It underperformed in the Panhandle and rural North Florida counties, where opposition topped 55%. Trulieve's stock price declined 47% in the week following the election. CEO Kim Rivers stated the company remained committed to Florida's medical market but acknowledged the defeat required strategic reassessment. Several multi-state operators announced workforce reductions and delayed Florida expansion plans.

Key Players

Trulieve Cannabis Corp.

Trulieve, headquartered in Quincy, Florida, emerged as the dominant force behind Amendment 3, contributing over 96% of total campaign funding. The company operates 194 retail locations across Florida and holds approximately 50% of the state's medical marijuana market share. CEO Kim Rivers, a former healthcare executive, founded Trulieve in 2015 and guided the company through its 2018 initial public offering on the Canadian Securities Exchange. Trulieve's business model relies on vertical integration, controlling cultivation, processing, and retail under Florida's closed-license system. The company cultivated and processed cannabis at facilities in Quincy and Midway, producing flower, concentrates, edibles, and topicals sold under the Trulieve, Cultivar Collection, and Momenta brands. The company's financial statements showed Florida operations generated $837 million in revenue during fiscal year 2023.

Smart & Safe Florida

Smart & Safe Florida, the political committee sponsoring Amendment 3, formed in April 2022 with Morgan Pons serving as treasurer. The committee hired strategic consulting firm Slade O'Brien to manage petition gathering, media strategy, and voter outreach. Campaign materials emphasized ending criminalization, generating tax revenue, and creating a regulated market with testing requirements and age restrictions.

Governor Ron DeSantis

Governor DeSantis orchestrated an unprecedented state-funded opposition campaign, deploying multiple agencies to defeat Amendment 3. DeSantis characterized the measure as a "corporate power grab" benefiting Trulieve at the expense of public health and safety. He appeared at press conferences across Florida warning that legalization would create a "weed stench" in public spaces and increase impaired driving. The DeSantis administration's tactics included directing the Florida Department of Health to create anti-Amendment 3 web content, instructing the Florida Department of Transportation to erect highway warning signs, and coordinating the Florida Agency for Health Care Administration's media campaign. Legal scholars questioned whether these activities violated Florida's prohibition on using state resources for political campaigns under Florida Statutes § 106.113.

Florida Agency for Health Care Administration

AHCA, led by Secretary Jason Weida, administered Florida's Medicaid program serving approximately 5.5 million beneficiaries. The agency's August 2026 grand jury scrutiny centered on approximately $10 million in expenditures for television and radio advertisements opposing Amendment 3. AHCA officials characterized the spending as public health education permissible under federal Medicaid administrative funding rules. The grand jury report disputed this characterization, finding the advertisements constituted political advocacy rather than health education.

John Morgan

Orlando attorney John Morgan, who funded the successful 2016 Amendment 2 campaign, notably declined to support Amendment 3. Morgan publicly criticized Trulieve's dominance of the measure and the absence of provisions for home cultivation or additional licenses. He stated that Amendment 3 would cement Trulieve's monopoly rather than create a competitive market benefiting consumers.

Drug Free America Foundation

The Drug Free America Foundation, a St. Petersburg-based advocacy organization, provided research and messaging support to Amendment 3 opponents. The organization's president, Laura Liddy, testified before legislative committees and appeared in media interviews warning about increased youth access and impaired driving if the measure passed.

Legal and Regulatory Framework

Florida's constitutional amendment process and existing cannabis statutes created a complex legal landscape for Amendment 3's consideration and implementation.

Constitutional Amendment Requirements

Article XI, Section 3 of the Florida Constitution establishes the citizen initiative process for constitutional amendments. Sponsors must collect signatures equal to 8% of votes cast in the previous presidential election, distributed across at least half of Florida's congressional districts. The Florida Supreme Court reviews proposed amendments for compliance with the single-subject rule and accuracy of ballot language. Article XI, Section 5 requires constitutional amendments to receive approval from 60% of voters, a threshold established by Amendment 3 to Article XI in 2006. This supermajority requirement makes Florida one of the most difficult states for citizen-initiated constitutional change.

Current Cannabis Legal Status

Florida Statutes § 893.13 classifies marijuana as a Schedule I controlled substance, making possession, sale, or cultivation criminal offenses absent medical authorization. Possession of 20 grams or less constitutes a first-degree misdemeanor punishable by up to one year imprisonment and a $1,000 fine. Possession exceeding 20 grams constitutes a third-degree felony punishable by up to five years imprisonment. Florida Statutes Chapter 381, Part X establishes the medical marijuana regulatory framework implementing Amendment 2. The law requires patients to obtain physician certification for qualifying conditions and register with the Department of Health's Office of Medical Marijuana Use. Patients may possess up to a 70-day supply as determined by their certifying physician, with smoking limited to 2.5 ounces per 35-day period.

Proposed Amendment 3 Framework

Amendment 3's constitutional language would have added Article X, Section 30 to the Florida Constitution. The text specified that adults 21 and older could possess, purchase, or use marijuana products for non-medical consumption. It prohibited possession, purchase, or use by individuals under 21 and maintained prohibitions on driving under the influence. The amendment directed the Department of Health to register entities to acquire, cultivate, process, manufacture, sell, and distribute marijuana products. It did not specify the number of licenses, application criteria, or whether new entrants beyond existing Medical Marijuana Treatment Centers could participate. This ambiguity led critics to argue the measure would preserve Trulieve's market dominance. The amendment prohibited the Legislature from enacting laws inconsistent with its provisions but allowed regulation of time, place, and manner of marijuana operations. It did not address taxation, leaving revenue structure to future legislative action. It did not permit home cultivation, distinguishing Florida's proposal from adult-use laws in states including Michigan, Arizona, and Missouri.

Federal Law Conflicts

The federal Controlled Substances Act, 21 U.S.C. § 812, classifies marijuana as a Schedule I substance, creating ongoing conflicts with state legalization efforts. Federal law prohibits manufacturing, distributing, or possessing marijuana regardless of state authorization. The Rohrabacher-Farr Amendment, renewed annually in federal appropriations bills, prohibits the Department of Justice from using funds to prevent states from implementing medical marijuana laws, but provides no protection for adult-use programs. Federal banking restrictions under the Bank Secrecy Act, 31 U.S.C. § 5318, and anti-money laundering regulations create operational challenges for cannabis businesses. Most federally insured banks decline to serve marijuana operators, forcing reliance on cash transactions and limited state-chartered financial institutions. Internal Revenue Code § 280E prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses, resulting in effective tax rates exceeding 70% for cannabis operators. Trulieve's financial statements showed $89 million in non-deductible expenses during fiscal 2023 due to 280E limitations.

The Grand Jury Investigation and Findings

A statewide grand jury empaneled in August 2025 to investigate Medicaid fraud issued a report in August 2026 concluding that the DeSantis administration misused approximately $10 million in Medicaid administrative funds to finance anti-Amendment 3 advertising. The grand jury, operating under Florida Statutes § 905.33, examined AHCA's expenditure of Medicaid dollars on television and radio advertisements that aired from September through November 2024. The advertisements featured messaging warning that Amendment 3 would increase youth marijuana access, create public safety risks, and burden Florida's healthcare system. AHCA Secretary Jason Weida testified that the agency classified the expenditures as permissible public health education under federal Medicaid administrative claiming rules at 42 C.F.R. § 433.15. Federal Medicaid law allows states to claim 50% federal matching funds for administrative activities including outreach and education related to program integrity and beneficiary health. The grand jury report rejected this characterization, finding that the advertisements constituted political advocacy rather than health education. The report noted that the advertisements urged viewers to "Vote No on Amendment 3" and featured messaging indistinguishable from campaign materials produced by political opposition groups. The report stated: "The use of Medicaid administrative funds for political advertising violates both federal Medicaid requirements and Florida's prohibition on using state resources for political campaigns." The report recommended that the Florida Legislature consider legislative action to prevent future misuse of agency funds for ballot measure campaigns. It did not recommend criminal charges against specific individuals, finding insufficient evidence of intentional fraud rather than aggressive interpretation of permissible administrative activities. AHCA issued a statement disputing the grand jury's characterization, maintaining that the advertisements constituted legitimate public health messaging about potential impacts to Medicaid beneficiaries and the state healthcare system. The agency noted that Amendment 3's passage could have affected Medicaid program administration by creating conflicts between federal prohibition and state legalization. Legal scholars noted that the grand jury findings raised questions about the DeSantis administration's broader use of state resources to oppose Amendment 3, including Department of Health web content and Department of Transportation signage. Florida Statutes § 106.113 prohibits using public funds for political advertisements supporting or opposing ballot measures, with violations constituting first-degree misdemeanors.

Market and Business Implications

Amendment 3's defeat preserved Florida's medical-only market structure, limiting growth prospects for multi-state operators while maintaining Trulieve's dominant position in a constrained regulatory environment.

Market Size and Projections

Florida's medical marijuana market generated approximately $2.1 billion in sales during 2023, making it the third-largest state medical program behind California and Arizona. Industry analysts projected that adult-use legalization would have expanded the total market to $6 billion annually by 2028, with recreational sales comprising approximately 70% of total revenue. The defeat of Amendment 3 limited market growth to medical program expansion, which analysts projected would reach $2.6 billion by 2028 based on patient enrollment trends. Florida's medical program served 823,000 registered patients as of October 2024, representing approximately 3.7% of the state's population. This penetration rate lagged behind mature medical markets including Arizona, Montana, and Oklahoma, suggesting continued enrollment growth potential.

Operator Impact

Trulieve's $145 million campaign investment represented approximately 17% of the company's fiscal 2023 revenue and significantly exceeded its $89 million in cash and equivalents as of June 2024. The company financed the campaign through a combination of operating cash flow, debt financing, and equity raises. Following the election defeat, Trulieve announced workforce reductions affecting approximately 400 employees and delayed planned facility expansions. Multi-state operators including Curaleaf, Verano Holdings, and Ayr Wellness had made strategic investments in Florida medical licenses anticipating adult-use legalization. Curaleaf operated 72 Florida dispensaries as of November 2024, representing its second-largest state footprint. The company's financial statements showed Florida operations generated $186 million in revenue during the first nine months of 2024. Following Amendment 3's defeat, Curaleaf announced it would slow Florida expansion and redirect capital to adult-use markets in New Jersey, New York, and Maryland. Smaller operators including Surterra Wellness, Liberty Health Sciences, and MÜV faced particular challenges. These companies lacked the geographic diversification of national MSOs and depended heavily on Florida market growth. Several operators explored strategic alternatives including asset sales or mergers to achieve scale efficiencies.

Pricing and Competition

Florida's medical marijuana prices remained elevated compared to adult-use markets due to limited competition and vertical integration requirements. Average flower prices ranged from $35 to $55 per eighth-ounce as of November 2024, compared to $20 to $35 in mature adult-use markets including Colorado, Oregon, and Michigan. The closed-license system prevented new entrants and limited competitive pressure. The Department of Health's 22 active licenses created an oligopolistic market structure with Trulieve controlling approximately 50% market share, followed by Curaleaf at 15%, Surterra at 8%, and MÜV at 7%. This concentration exceeded most other state markets and contributed to pricing power for dominant operators.

Investment and Capital Markets

Cannabis equity markets reacted negatively to Amendment 3's defeat, with the AdvisorShares Pure US Cannabis ETF declining 23% in the week following the election. Trulieve's stock price fell from $8.47 per share on November 4, 2024, to $4.52 per share on November 12, 2024, a 47% decline. The company's market capitalization contracted from approximately $1.8 billion to $950 million. Debt markets also reflected increased risk perception. Trulieve's senior secured notes due 2026 with a 9.75% coupon traded down from 94 cents on the dollar to 78 cents following the election, implying a yield-to-maturity exceeding 18%. Credit rating agencies placed the company's debt under review for potential downgrade. Cannabis-focused venture capital and private equity firms reduced Florida deployment following the election. Poseidon Investment Management, Navy Capital, and Panther Capital announced they would prioritize investments in states with adult-use programs or clear paths to legalization rather than medical-only markets.

What Experts Say

Industry analysts, legal scholars, and policy advocates offered divergent assessments of Amendment 3's defeat and its implications for cannabis reform. Morgan Fox, political director of the National Organization for the Reform of Marijuana Laws, stated that the 60% threshold requirement created an unrealistic barrier to voter-initiated reform in Florida. According to Fox, the measure's 56% support demonstrated clear majority preference for legalization despite the defeat. He noted that most states require simple majorities for constitutional amendments, making Florida an outlier. Karen O'Keefe, director of state policies at the Marijuana Policy Project, characterized Governor DeSantis's opposition campaign as unprecedented in its use of state resources. According to O'Keefe, the deployment of multiple agencies to defeat a ballot measure raised serious questions about appropriate boundaries between governance and political advocacy. She stated that the grand jury findings vindicated concerns about improper use of public funds. Pablo Zuanic, managing director and senior analyst at Zuanic & Associates, noted that Amendment 3's defeat reflected broader challenges facing cannabis ballot measures in 2024. According to Zuanic, measures in Florida, North Dakota, and South Dakota all failed despite significant financial support, suggesting voter skepticism about legalization had increased compared to the 2016-2020 period when most measures passed. He attributed this shift to concerns about impaired driving, youth access, and corporate consolidation. Robert Mikos, professor at Vanderbilt Law School and cannabis law expert, stated that Amendment 3's failure to address licensing structure represented a critical flaw. According to Mikos, voters increasingly scrutinize whether legalization measures create competitive markets or cement incumbent advantages. He noted that successful 2020 measures in Arizona, Montana, and New Jersey included provisions for new licenses and social equity applicants, while Florida's measure preserved the existing oligopoly. Ben Pollara, executive director of Florida for Care and veteran of multiple Florida cannabis campaigns, stated that the DeSantis administration's opposition made the difference in a close race. According to Pollara, internal polling showed Amendment 3 tracking at 64% support in August 2024 before the state-funded advertising campaign launched. He stated that the grand jury findings confirmed that taxpayer dollars improperly influenced the election outcome. Trulieve CEO Kim Rivers stated in a November 2024 earnings call that the company remained committed to Florida despite the setback. According to Rivers, Trulieve would continue advocating for cannabis reform through legislative channels and potential future ballot measures. She noted that the company's investment demonstrated its long-term confidence in Florida's market potential.

What's Next

The defeat of Amendment 3 leaves Florida cannabis reform advocates with limited near-term options, while the grand jury findings may prompt legislative and legal responses.

Legislative Reform Prospects

The Florida Legislature has shown limited appetite for cannabis liberalization through statutory channels. Republican leadership in both chambers opposed Amendment 3 and has blocked previous bills to expand the medical program or decriminalize possession. The 2025 legislative session saw no cannabis reform bills receive committee hearings. Some advocates suggested pursuing incremental reforms including home cultivation for medical patients, expanded qualifying conditions, or possession decriminalization. However, the political dynamics following Amendment 3's defeat made legislative action unlikely before the 2026 gubernatorial election.

Future Ballot Measures

Smart & Safe Florida could pursue a revised amendment for the 2026 ballot, though the timeline for signature gathering would be compressed. Any future measure would likely need to address criticisms of the 2024 version, including licensing structure, home cultivation, and social equity provisions. The 60% threshold requirement remained a significant obstacle. Only two citizen-initiated constitutional amendments have passed since Florida adopted the supermajority requirement in 2006: Amendment 2 in 2016 and Amendment 4 restoring voting rights in 2018. Both received over 64% support, suggesting that measures need substantial margins to overcome late-breaking opposition.

Legal and Legislative Responses to Grand Jury Findings

The August 2026 grand jury report prompted calls for legislative action to prevent future misuse of agency funds for political campaigns. Democratic legislators introduced bills to strengthen Florida Statutes § 106.113 by explicitly prohibiting state agencies from producing or distributing materials advocating for or against ballot measures. Advocacy groups including the ACLU of Florida and Common Cause Florida called for investigations into whether DeSantis administration officials violated campaign finance laws. The Florida Commission on Ethics, which enforces Chapter 106, faced questions about its jurisdiction over agency expenditures characterized as public education.

Federal Rescheduling Impact

The U.S. Drug Enforcement Administration's ongoing consideration of rescheduling marijuana from Schedule I to Schedule III under the Controlled Substances Act could affect Florida's cannabis landscape. Rescheduling would eliminate Internal Revenue Code § 280E tax penalties, improving operator profitability and potentially reducing consumer prices. However, rescheduling would not resolve the fundamental conflict between federal prohibition and state legalization. Cannabis would remain a controlled substance subject to FDA regulation, and interstate commerce would remain prohibited absent further federal reform.

2026 Gubernatorial Election

Florida's 2026 gubernatorial election could reshape cannabis policy dynamics. Governor DeSantis faced term limits and could not seek reelection. Potential candidates including Attorney General Ashley Moody, Chief Financial Officer Jimmy Patronis, and former U.S. Representative Charlie Crist held varying positions on cannabis reform. A governor supportive of legalization could decline to deploy state resources against future ballot measures and could direct agencies to implement medical program reforms expanding access and reducing costs.

Further Reading

• Florida Constitution Article X, Section 29 (Amendment 2 - Medical Marijuana) - https://www.flsenate.gov/Laws/Constitution
• Florida Statutes Chapter 381, Part X (Medical Marijuana) - https://www.flsenate.gov/Laws/Statutes/2024/Chapter381/Part_X
• Florida Department of Health Office of Medical Marijuana Use - https://knowthefactsmmj.com/
• Smart & Safe Florida Amendment 3 Full Text - https://dos.fl.gov/elections/laws-rules/constitutional-amendments/
• Florida Supreme Court Advisory Opinion on Amendment 3 (April 2024) - https://www.floridasupremecourt.org/
• Florida Division of Elections Campaign Finance Database - https://dos.fl.gov/elections/campaign-finance/
• Trulieve Cannabis Corp. SEC Filings and Financial Statements - https://www.sec.gov/edgar/browse/?CIK=1737927
• Controlled Substances Act, 21 U.S.C. § 812 - https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Internal Revenue Code § 280E - https://www.law.cornell.edu/uscode/text/26/280E
• Florida Statutes § 106.113 (Prohibition on Use of Public Funds for Political Purposes) - https://www.flsenate.gov/Laws/Statutes/2024/106.113
• National Organization for the Reform of Marijuana Laws Florida Chapter - https://www.flnorml.org/
• Marijuana Policy Project State Policy Database - https://www.mpp.org/states/